ECOG-ACRIN opened the NCI-MATCH precision medicine trial, the largest, most scientifically rigorous precision medicine trial in cancer to date.
NCI-MATCH seeks to determine whether matching certain drugs or drug combinations to people whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.
Known to doctors as the phase II trial EAY131, the treatment focuses on molecular abnormalities of patient tumors instead of the organ sites of the cancer.
NCI-MATCH will match patients with one of 22 treatments to test the use of each specific drug or drug combination targeted to a particular gene abnormality. It is open to medical facilities with 10 treatments, and the additional 12 treatments will be added to the trial within the next several months.
Patients can enroll in the trial on a rolling basis as hospitals and cancer centers join and as the additional treatments become available.
The trial seeks to enroll for genetic testing about 3,000 adults, 18 years of age and older, with any type of solid tumor or lymphoma that has returned or gotten worse after standard systemic therapy. Patients may also be eligible for screening if they have a rare type of cancer for which there is no standard treatment.
All patients considering the trial will need to have a new biopsy and their tumor cells will need to undergo genetic testing to see whether they contain one of the gene mutations being studied.
Trial researchers expect that about one-third of the patients screened will have one or more molecular abnormalities that match one of the 22 treatments being studied. If so, they will be further evaluated to determine if they are able to be treated as part of the trial.
There will be 35 patients enrolled for each drug/drug combination being studied. The trial’s design calls for at least 25 percent of the 1,000-patient enrollment to be people with rare types of cancer.
ECOG-ACRIN is coordinating the genetic testing. It also supports all trial sites with training, laboratory services, trial assignments, biostatistical support, data management, auditing, quality control, and public awareness. The study was co-developed by the ECOG-ACRIN Cancer Research Group and NCI.
